Skip to main content
Top
Published in: Arthritis Research & Therapy 1/2024

Open Access 01-12-2024 | Lupus Nephritis | Research

Macrophage subpopulations in pediatric patients with lupus nephritis and other inflammatory diseases affecting the kidney

Authors: Mira Sandersfeld, Maike Büttner-Herold, Fulvia Ferrazzi, Kerstin Amann, Kerstin Benz, Christoph Daniel

Published in: Arthritis Research & Therapy | Issue 1/2024

Login to get access

Abstract

Background

Macrophages play an important role in the pathogenesis of lupus nephritis (LN), but less is known about macrophage subtypes in pediatric LN. Here we compared renal inflammation in LN with other inflammatory pediatric kidney diseases and assessed whether inflammation correlates with clinical parameters.

Methods

Using immunofluorescence microscopy, we analyzed renal biopsies from 20 pediatric patients with lupus nephritis (ISN/RPS classes II–V) and pediatric controls with other inflammatory kidney diseases for infiltration with M1-like (CD68 + /CD206 − , CD68 + /CD163 −), M2a-like (CD206 + /CD68 +), and M2c-like macrophages (CD163 + /CD68 +) as well as CD3 + T-cells, CD20 + B-cells, and MPO + neutrophilic granulocytes. In addition, the correlation of macrophage infiltration with clinical parameters at the time of renal biopsy, e.g., eGFR and serum urea, was investigated. Macrophage subpopulations were compared with data from a former study of adult LN patients.

Results

The frequency of different macrophage subtypes in biopsies of pediatric LN was dependent on ISN/RPS class and showed the most pronounced M1-like macrophage infiltration in patients with LN class IV, whereas M2c-like macrophages were most abundant in class III and IV. Interestingly, on average, only half as many macrophages were found in renal biopsies of pediatric LN compared to adult patients with LN. The distribution of frequencies of macrophage subpopulations, however, was different for CD68 + CD206 + (M2a-like) but comparable for CD68 + CD163 − (M1-like) CD68 + CD163 + (M2c-like) cells in pediatric and adult patients. Compared to other inflammatory kidney diseases in children, fewer macrophages and other inflammatory cells were found in kidney biopsies of LN. Depending on the disease, the frequency of individual immune cell types varied, but we were unable to confirm disease-specific inflammatory signatures in our study due to the small number of pediatric cases. Worsened renal function, measured as elevated serum urea and decreased eGFR, correlated particularly strongly with the number of CD68 + /CD163 − M1-like macrophages and CD20 + B cells in pediatric inflammatory kidney disease.

Conclusion

Although M1-like macrophages play a greater role in pediatric LN patients than in adult LN patients, M2-like macrophages appear to be key players and are more abundant in other pediatric inflammatory kidney diseases compared to LN.
Appendix
Available only for authorised users
Literature
1.
go back to reference Sada KE, Makino H. Usefulness of ISN/RPS classification of lupus nephritis. J Korean Med Sci. 2009;24 Suppl(Suppl 1):S7-10.PubMedCrossRef Sada KE, Makino H. Usefulness of ISN/RPS classification of lupus nephritis. J Korean Med Sci. 2009;24 Suppl(Suppl 1):S7-10.PubMedCrossRef
2.
go back to reference Bajema IM, Wilhelmus S, Alpers CE, Bruijn JA, Colvin RB, Cook HT, D’Agati VD, Ferrario F, Haas M, Jennette JC, et al. Revision of the International Society of Nephrology/Renal Pathology Society classification for lupus nephritis: clarification of definitions, and modified National Institutes of Health activity and chronicity indices. Kidney Int. 2018;93(4):789–96.PubMedCrossRef Bajema IM, Wilhelmus S, Alpers CE, Bruijn JA, Colvin RB, Cook HT, D’Agati VD, Ferrario F, Haas M, Jennette JC, et al. Revision of the International Society of Nephrology/Renal Pathology Society classification for lupus nephritis: clarification of definitions, and modified National Institutes of Health activity and chronicity indices. Kidney Int. 2018;93(4):789–96.PubMedCrossRef
5.
go back to reference Cervera R, Khamashta MA, Font J, Sebastiani GD, Gil A, Lavilla P, Doménech I, Aydintug AO, Jedryka-Góral A, de Ramón E, et al. Systemic lupus erythematosus: clinical and immunologic patterns of disease expression in a cohort of 1,000 patients. The European Working Party on Systemic Lupus Erythematosus. Medicine (Baltimore). 1993;72(2):113–24.PubMedCrossRef Cervera R, Khamashta MA, Font J, Sebastiani GD, Gil A, Lavilla P, Doménech I, Aydintug AO, Jedryka-Góral A, de Ramón E, et al. Systemic lupus erythematosus: clinical and immunologic patterns of disease expression in a cohort of 1,000 patients. The European Working Party on Systemic Lupus Erythematosus. Medicine (Baltimore). 1993;72(2):113–24.PubMedCrossRef
7.
go back to reference Bijl M, Reefman E, Horst G, Limburg PC, Kallenberg CG. Reduced uptake of apoptotic cells by macrophages in systemic lupus erythematosus: correlates with decreased serum levels of complement. Ann Rheum Dis. 2006;65(1):57–63.PubMedCrossRef Bijl M, Reefman E, Horst G, Limburg PC, Kallenberg CG. Reduced uptake of apoptotic cells by macrophages in systemic lupus erythematosus: correlates with decreased serum levels of complement. Ann Rheum Dis. 2006;65(1):57–63.PubMedCrossRef
8.
go back to reference Marto N, Bertolaccini ML, Calabuig E, Hughes GR, Khamashta MA. Anti-C1q antibodies in nephritis: correlation between titres and renal disease activity and positive predictive value in systemic lupus erythematosus. Ann Rheum Dis. 2005;64(3):444–8.PubMedCrossRef Marto N, Bertolaccini ML, Calabuig E, Hughes GR, Khamashta MA. Anti-C1q antibodies in nephritis: correlation between titres and renal disease activity and positive predictive value in systemic lupus erythematosus. Ann Rheum Dis. 2005;64(3):444–8.PubMedCrossRef
9.
go back to reference Trendelenburg M, Lopez-Trascasa M, Potlukova E, Moll S, Regenass S, Frémeaux-Bacchi V, Martinez-Ara J, Jancova E, Picazo ML, Honsova E, et al. High prevalence of anti-C1q antibodies in biopsy-proven active lupus nephritis. Nephrol Dial Transplant. 2006;21(11):3115–21.PubMedCrossRef Trendelenburg M, Lopez-Trascasa M, Potlukova E, Moll S, Regenass S, Frémeaux-Bacchi V, Martinez-Ara J, Jancova E, Picazo ML, Honsova E, et al. High prevalence of anti-C1q antibodies in biopsy-proven active lupus nephritis. Nephrol Dial Transplant. 2006;21(11):3115–21.PubMedCrossRef
10.
go back to reference Walport MJ, Davies KA, Botto M. C1q and systemic lupus erythematosus. Immunobiology. 1998;199(2):265–85.PubMedCrossRef Walport MJ, Davies KA, Botto M. C1q and systemic lupus erythematosus. Immunobiology. 1998;199(2):265–85.PubMedCrossRef
11.
go back to reference Frangou E, Georgakis S, Bertsias G. Update on the cellular and molecular aspects of lupus nephritis. Clin Immunol. 2020;216:108445.PubMedCrossRef Frangou E, Georgakis S, Bertsias G. Update on the cellular and molecular aspects of lupus nephritis. Clin Immunol. 2020;216:108445.PubMedCrossRef
12.
13.
go back to reference Schiffer L, Bethunaickan R, Ramanujam M, Huang W, Schiffer M, Tao H, Madaio MP, Bottinger EP, Davidson A. Activated renal macrophages are markers of disease onset and disease remission in lupus nephritis. J Immunol. 2008;180(3):1938–47.PubMedCrossRef Schiffer L, Bethunaickan R, Ramanujam M, Huang W, Schiffer M, Tao H, Madaio MP, Bottinger EP, Davidson A. Activated renal macrophages are markers of disease onset and disease remission in lupus nephritis. J Immunol. 2008;180(3):1938–47.PubMedCrossRef
14.
go back to reference Zhang T, Wang M, Zhang J, Feng X, Liu Z, Cheng Z. Association between tubulointerstitial CD8+T cells and renal prognosis in lupus nephritis. Int Immunopharmacol. 2021;99:107877.PubMedCrossRef Zhang T, Wang M, Zhang J, Feng X, Liu Z, Cheng Z. Association between tubulointerstitial CD8+T cells and renal prognosis in lupus nephritis. Int Immunopharmacol. 2021;99:107877.PubMedCrossRef
15.
go back to reference Maroz N, Segal MS. Lupus nephritis and end-stage kidney disease. Am J Med Sci. 2013;346(4):319–23.PubMedCrossRef Maroz N, Segal MS. Lupus nephritis and end-stage kidney disease. Am J Med Sci. 2013;346(4):319–23.PubMedCrossRef
16.
go back to reference Xipell M, Lledó GM, Egan AC, Tamirou F, Del Castillo CS, Rovira J, Gómez-Puerta JA, García-Herrera A, Cervera R, Kronbichler A, et al. From systemic lupus erythematosus to lupus nephritis: The evolving road to targeted therapies. Autoimmun Rev. 2023;22(10):103404.PubMedCrossRef Xipell M, Lledó GM, Egan AC, Tamirou F, Del Castillo CS, Rovira J, Gómez-Puerta JA, García-Herrera A, Cervera R, Kronbichler A, et al. From systemic lupus erythematosus to lupus nephritis: The evolving road to targeted therapies. Autoimmun Rev. 2023;22(10):103404.PubMedCrossRef
18.
go back to reference Bethunaickan R, Berthier CC, Ramanujam M, Sahu R, Zhang W, Sun Y, Bottinger EP, Ivashkiv L, Kretzler M, Davidson A. A unique hybrid renal mononuclear phagocyte activation phenotype in murine systemic lupus erythematosus nephritis. J Immunol. 2011;186(8):4994–5003.PubMedCrossRef Bethunaickan R, Berthier CC, Ramanujam M, Sahu R, Zhang W, Sun Y, Bottinger EP, Ivashkiv L, Kretzler M, Davidson A. A unique hybrid renal mononuclear phagocyte activation phenotype in murine systemic lupus erythematosus nephritis. J Immunol. 2011;186(8):4994–5003.PubMedCrossRef
19.
go back to reference Chen J, Cui L, Ouyang J, Wang J, Xu W. Clinicopathological significance of tubulointerstitial CD68 macrophages in proliferative lupus nephritis. Clin Rheumatol. 2022;41(9):2729–36.PubMedCrossRef Chen J, Cui L, Ouyang J, Wang J, Xu W. Clinicopathological significance of tubulointerstitial CD68 macrophages in proliferative lupus nephritis. Clin Rheumatol. 2022;41(9):2729–36.PubMedCrossRef
20.
go back to reference Jing C, Castro-Dopico T, Richoz N, Tuong ZK, Ferdinand JR, Lok LSC, Loudon KW, Banham GD, Mathews RJ, Cader Z, et al. Macrophage metabolic reprogramming presents a therapeutic target in lupus nephritis. Proc Natl Acad Sci U S A. 2020;117(26):15160–71.ADSPubMedPubMedCentralCrossRef Jing C, Castro-Dopico T, Richoz N, Tuong ZK, Ferdinand JR, Lok LSC, Loudon KW, Banham GD, Mathews RJ, Cader Z, et al. Macrophage metabolic reprogramming presents a therapeutic target in lupus nephritis. Proc Natl Acad Sci U S A. 2020;117(26):15160–71.ADSPubMedPubMedCentralCrossRef
21.
go back to reference Orme J, Mohan C. Macrophage subpopulations in systemic lupus erythematosus. Discov Med. 2012;13(69):151–8.PubMed Orme J, Mohan C. Macrophage subpopulations in systemic lupus erythematosus. Discov Med. 2012;13(69):151–8.PubMed
22.
go back to reference Mantovani A, Sica A, Sozzani S, Allavena P, Vecchi A, Locati M. The chemokine system in diverse forms of macrophage activation and polarization. Trends Immunol. 2004;25(12):677–86.PubMedCrossRef Mantovani A, Sica A, Sozzani S, Allavena P, Vecchi A, Locati M. The chemokine system in diverse forms of macrophage activation and polarization. Trends Immunol. 2004;25(12):677–86.PubMedCrossRef
23.
go back to reference Ndisang JF, Mishra M. The heme oxygenase system selectively suppresses the proinflammatory macrophage m1 phenotype and potentiates insulin signaling in spontaneously hypertensive rats. Am J Hypertens. 2013;26(9):1123–31.PubMedCrossRef Ndisang JF, Mishra M. The heme oxygenase system selectively suppresses the proinflammatory macrophage m1 phenotype and potentiates insulin signaling in spontaneously hypertensive rats. Am J Hypertens. 2013;26(9):1123–31.PubMedCrossRef
24.
go back to reference Kulkarni O, Pawar RD, Purschke W, Eulberg D, Selve N, Buchner K, Ninichuk V, Segerer S, Vielhauer V, Klussmann S, et al. Spiegelmer inhibition of CCL2/MCP-1 ameliorates lupus nephritis in MRL-(Fas)lpr mice. J Am Soc Nephrol. 2007;18(8):2350–8.PubMedCrossRef Kulkarni O, Pawar RD, Purschke W, Eulberg D, Selve N, Buchner K, Ninichuk V, Segerer S, Vielhauer V, Klussmann S, et al. Spiegelmer inhibition of CCL2/MCP-1 ameliorates lupus nephritis in MRL-(Fas)lpr mice. J Am Soc Nephrol. 2007;18(8):2350–8.PubMedCrossRef
25.
go back to reference Olmes G, Büttner-Herold M, Ferrazzi F, Distel L, Amann K, Daniel C. CD163+ M2c-like macrophages predominate in renal biopsies from patients with lupus nephritis. Arthritis Res Ther. 2016;18:90.PubMedPubMedCentralCrossRef Olmes G, Büttner-Herold M, Ferrazzi F, Distel L, Amann K, Daniel C. CD163+ M2c-like macrophages predominate in renal biopsies from patients with lupus nephritis. Arthritis Res Ther. 2016;18:90.PubMedPubMedCentralCrossRef
26.
go back to reference Bankhead P, Loughrey MB, Fernández JA, Dombrowski Y, McArt DG, Dunne PD, McQuaid S, Gray RT, Murray LJ, Coleman HG, et al. QuPath: Open source software for digital pathology image analysis. Sci Rep. 2017;7(1):16878.ADSPubMedPubMedCentralCrossRef Bankhead P, Loughrey MB, Fernández JA, Dombrowski Y, McArt DG, Dunne PD, McQuaid S, Gray RT, Murray LJ, Coleman HG, et al. QuPath: Open source software for digital pathology image analysis. Sci Rep. 2017;7(1):16878.ADSPubMedPubMedCentralCrossRef
27.
go back to reference Schwartz GJ, Muñoz A, Schneider MF, Mak RH, Kaskel F, Warady BA, Furth SL. New equations to estimate GFR in children with CKD. J Am Soc Nephrol. 2009;20(3):629–37.PubMedPubMedCentralCrossRef Schwartz GJ, Muñoz A, Schneider MF, Mak RH, Kaskel F, Warady BA, Furth SL. New equations to estimate GFR in children with CKD. J Am Soc Nephrol. 2009;20(3):629–37.PubMedPubMedCentralCrossRef
28.
go back to reference Hill GS, Delahousse M, Nochy D, Rémy P, Mignon F, Méry JP, Bariéty J. Predictive power of the second renal biopsy in lupus nephritis: significance of macrophages. Kidney Int. 2001;59(1):304–16.PubMedCrossRef Hill GS, Delahousse M, Nochy D, Rémy P, Mignon F, Méry JP, Bariéty J. Predictive power of the second renal biopsy in lupus nephritis: significance of macrophages. Kidney Int. 2001;59(1):304–16.PubMedCrossRef
29.
go back to reference Kwant LE, Vegting Y, Tsang ASMWP, Kwakernaak AJ, Vogt L, Voskuyl AE, van Vollenhoven RF, de Winther MPJ, Bemelman FJ, Anders HJ, et al. Macrophages in lupus nephritis: exploring a potential new therapeutic avenue. Autoimmun Rev. 2022;21(12):103211.PubMedCrossRef Kwant LE, Vegting Y, Tsang ASMWP, Kwakernaak AJ, Vogt L, Voskuyl AE, van Vollenhoven RF, de Winther MPJ, Bemelman FJ, Anders HJ, et al. Macrophages in lupus nephritis: exploring a potential new therapeutic avenue. Autoimmun Rev. 2022;21(12):103211.PubMedCrossRef
30.
go back to reference Richoz N, Tuong ZK, Loudon KW, Patiño-Martínez E, Ferdinand JR, Portet A, Bashant KR, Thevenon E, Rucci F, Hoyler T, et al. Distinct pathogenic roles for resident and monocyte-derived macrophages in lupus nephritis. JCI Insight. 2022;7(21):e159751.PubMedPubMedCentralCrossRef Richoz N, Tuong ZK, Loudon KW, Patiño-Martínez E, Ferdinand JR, Portet A, Bashant KR, Thevenon E, Rucci F, Hoyler T, et al. Distinct pathogenic roles for resident and monocyte-derived macrophages in lupus nephritis. JCI Insight. 2022;7(21):e159751.PubMedPubMedCentralCrossRef
31.
go back to reference Iwata Y, Boström EA, Menke J, Rabacal WA, Morel L, Wada T, Kelley VR. Aberrant macrophages mediate defective kidney repair that triggers nephritis in lupus-susceptible mice. J Immunol. 2012;188(9):4568–80.PubMedCrossRef Iwata Y, Boström EA, Menke J, Rabacal WA, Morel L, Wada T, Kelley VR. Aberrant macrophages mediate defective kidney repair that triggers nephritis in lupus-susceptible mice. J Immunol. 2012;188(9):4568–80.PubMedCrossRef
32.
go back to reference Boswell JM, Yui MA, Burt DW, Kelley VE. Increased tumor necrosis factor and IL-1 beta gene expression in the kidneys of mice with lupus nephritis. J Immunol. 1988;141(9):3050–4.PubMedCrossRef Boswell JM, Yui MA, Burt DW, Kelley VE. Increased tumor necrosis factor and IL-1 beta gene expression in the kidneys of mice with lupus nephritis. J Immunol. 1988;141(9):3050–4.PubMedCrossRef
33.
go back to reference Horuluoglu B, Bayik D, Kayraklioglu N, Goguet E, Kaplan MJ, Klinman DM. PAM3 supports the generation of M2-like macrophages from lupus patient monocytes and improves disease outcome in murine lupus. J Autoimmun. 2019;99:24–32.PubMedPubMedCentralCrossRef Horuluoglu B, Bayik D, Kayraklioglu N, Goguet E, Kaplan MJ, Klinman DM. PAM3 supports the generation of M2-like macrophages from lupus patient monocytes and improves disease outcome in murine lupus. J Autoimmun. 2019;99:24–32.PubMedPubMedCentralCrossRef
34.
go back to reference Li F, Yang Y, Zhu X, Huang L, Xu J. Macrophage polarization modulates development of systemic lupus erythematosus. Cell Physiol Biochem. 2015;37(4):1279–88.PubMedCrossRef Li F, Yang Y, Zhu X, Huang L, Xu J. Macrophage polarization modulates development of systemic lupus erythematosus. Cell Physiol Biochem. 2015;37(4):1279–88.PubMedCrossRef
35.
go back to reference Li J, Yu YF, Liu CH, Wang CM. Significance of M2 macrophages in glomerulonephritis with crescents. Pathol Res Pract. 2017;213(9):1215–20.PubMedCrossRef Li J, Yu YF, Liu CH, Wang CM. Significance of M2 macrophages in glomerulonephritis with crescents. Pathol Res Pract. 2017;213(9):1215–20.PubMedCrossRef
36.
go back to reference Kishimoto D, Kirino Y, Tamura M, Takeno M, Kunishita Y, Takase-Minegishi K, Nakano H, Kato I, Nagahama K, Yoshimi R, et al. Dysregulated heme oxygenase-1(low) M2-like macrophages augment lupus nephritis via Bach1 induced by type I interferons. Arthritis Res Ther. 2018;20(1):64.PubMedPubMedCentralCrossRef Kishimoto D, Kirino Y, Tamura M, Takeno M, Kunishita Y, Takase-Minegishi K, Nakano H, Kato I, Nagahama K, Yoshimi R, et al. Dysregulated heme oxygenase-1(low) M2-like macrophages augment lupus nephritis via Bach1 induced by type I interferons. Arthritis Res Ther. 2018;20(1):64.PubMedPubMedCentralCrossRef
37.
go back to reference Kaykı G, Orhan D, Gülhan B, Topaloğlu R, Akçören Z, Düzova A, Özaltın F, Özen S, Bilginer Y, Güçer Ş. Glomerulonephritis with crescents in childhood; etiologies and significance of M2 macrophages. Turk J Pediatr. 2022;64(1):59–68.PubMedCrossRef Kaykı G, Orhan D, Gülhan B, Topaloğlu R, Akçören Z, Düzova A, Özaltın F, Özen S, Bilginer Y, Güçer Ş. Glomerulonephritis with crescents in childhood; etiologies and significance of M2 macrophages. Turk J Pediatr. 2022;64(1):59–68.PubMedCrossRef
38.
go back to reference Zhao L, David MZ, Hyjek E, Chang A, Meehan SM. M2 macrophage infiltrates in the early stages of ANCA-associated pauci-immune necrotizing GN. Clin J Am Soc Nephrol. 2015;10(1):54–62.PubMedCrossRef Zhao L, David MZ, Hyjek E, Chang A, Meehan SM. M2 macrophage infiltrates in the early stages of ANCA-associated pauci-immune necrotizing GN. Clin J Am Soc Nephrol. 2015;10(1):54–62.PubMedCrossRef
39.
go back to reference Dias CB, Malafronte P, Lee J, Resende A, Jorge L, Pinheiro CC, Malheiros D, Woronik V. Role of renal expression of CD68 in the long-term prognosis of proliferative lupus nephritis. J Nephrol. 2017;30(1):87–94.PubMedCrossRef Dias CB, Malafronte P, Lee J, Resende A, Jorge L, Pinheiro CC, Malheiros D, Woronik V. Role of renal expression of CD68 in the long-term prognosis of proliferative lupus nephritis. J Nephrol. 2017;30(1):87–94.PubMedCrossRef
40.
go back to reference Zhang T, Li H, Vanarsa K, Gidley G, Mok CC, Petri M, Saxena R, Mohan C. Association of urine sCD163 with proliferative lupus nephritis, fibrinoid necrosis, cellular crescents and intrarenal M2 macrophages. Front Immunol. 2020;11:671.PubMedPubMedCentralCrossRef Zhang T, Li H, Vanarsa K, Gidley G, Mok CC, Petri M, Saxena R, Mohan C. Association of urine sCD163 with proliferative lupus nephritis, fibrinoid necrosis, cellular crescents and intrarenal M2 macrophages. Front Immunol. 2020;11:671.PubMedPubMedCentralCrossRef
41.
go back to reference Yang G, Guo N, Yin J, Wu J. Elevated soluble CD163 predicts renal function deterioration in lupus nephritis: a cohort study in Eastern China. J Int Med Res. 2021;49(11):3000605211049963.PubMedCrossRef Yang G, Guo N, Yin J, Wu J. Elevated soluble CD163 predicts renal function deterioration in lupus nephritis: a cohort study in Eastern China. J Int Med Res. 2021;49(11):3000605211049963.PubMedCrossRef
42.
go back to reference Anders HJ, Ryu M. Renal microenvironments and macrophage phenotypes determine progression or resolution of renal inflammation and fibrosis. Kidney Int. 2011;80(9):915–25.PubMedCrossRef Anders HJ, Ryu M. Renal microenvironments and macrophage phenotypes determine progression or resolution of renal inflammation and fibrosis. Kidney Int. 2011;80(9):915–25.PubMedCrossRef
44.
go back to reference Bao L, Osawe I, Puri T, Lambris JD, Haas M, Quigg RJ. C5a promotes development of experimental lupus nephritis which can be blocked with a specific receptor antagonist. Eur J Immunol. 2005;35(8):2496–506.PubMedCrossRef Bao L, Osawe I, Puri T, Lambris JD, Haas M, Quigg RJ. C5a promotes development of experimental lupus nephritis which can be blocked with a specific receptor antagonist. Eur J Immunol. 2005;35(8):2496–506.PubMedCrossRef
45.
go back to reference Daniel C, Leppkes M, Munoz LE, Schley G, Schett G, Herrmann M. Extracellular DNA traps in inflammation, injury and healing. Nat Rev Nephrol. 2019;15(9):559–75.PubMedCrossRef Daniel C, Leppkes M, Munoz LE, Schley G, Schett G, Herrmann M. Extracellular DNA traps in inflammation, injury and healing. Nat Rev Nephrol. 2019;15(9):559–75.PubMedCrossRef
46.
go back to reference Xue J, Schmidt SV, Sander J, Draffehn A, Krebs W, Quester I, De Nardo D, Gohel TD, Emde M, Schmidleithner L, et al. Transcriptome-based network analysis reveals a spectrum model of human macrophage activation. Immunity. 2014;40(2):274–88.PubMedPubMedCentralCrossRef Xue J, Schmidt SV, Sander J, Draffehn A, Krebs W, Quester I, De Nardo D, Gohel TD, Emde M, Schmidleithner L, et al. Transcriptome-based network analysis reveals a spectrum model of human macrophage activation. Immunity. 2014;40(2):274–88.PubMedPubMedCentralCrossRef
Metadata
Title
Macrophage subpopulations in pediatric patients with lupus nephritis and other inflammatory diseases affecting the kidney
Authors
Mira Sandersfeld
Maike Büttner-Herold
Fulvia Ferrazzi
Kerstin Amann
Kerstin Benz
Christoph Daniel
Publication date
01-12-2024
Publisher
BioMed Central
Published in
Arthritis Research & Therapy / Issue 1/2024
Electronic ISSN: 1478-6362
DOI
https://doi.org/10.1186/s13075-024-03281-1

Other articles of this Issue 1/2024

Arthritis Research & Therapy 1/2024 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine